PMID- 28329473
OWN - NLM
STAT- MEDLINE
DCOM- 20171011
LR  - 20171011
IS  - 1087-2108 (Electronic)
IS  - 1087-2108 (Linking)
VI  - 23
IP  - 1
DP  - 2017 Jan 15
TI  - Successful treatment of recalcitrant discoid lupus erythematosus with
      ustekinumab.
LID - 13030/qt206538zm [pii]
AB  - We report a 52-year old woman with a 28-year historyof disfiguring facial discoid
      lupus erythematosus(DLE), persistent despite both classical therapiesand
      rituximab. Ustekinumab 45 mg was started incombination with methotrexate and
      intralesionalcorticosteroids. Methotrexate and intralesionalcorticosteroids were 
      withdrawn 30 months later andustekinumab maintained as monotherapy. Fortyeight
      months later stable improvement was achievedwithout side effects. Only nine
      patients with cutaneouslupus erythematosus (CLE) treated with ustekinumabhave
      been reported to date. Ustekinumab could be apromising alternative in severe and 
      recalcitrant casesof CLE. Possibly, the Th17-inflammation pathway isplaying a
      role in these patients.
FAU - Romero-Mate, Alberto
AU  - Romero-Mate A
AD  - Department of Dermatology, Hospital Universitario de Fuenlabrada, Madrid.
      aromerom@salud.madrid.org.
FAU - Garcia-Donoso, Carmen
AU  - Garcia-Donoso C
FAU - Hernandez-Nunez, Almudena
AU  - Hernandez-Nunez A
FAU - Martinez-Moran, Cristina
AU  - Martinez-Moran C
FAU - Moreno-Torres, Amalia
AU  - Moreno-Torres A
FAU - Borbujo-Martinez, Jesus
AU  - Borbujo-Martinez J
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20170115
PL  - United States
TA  - Dermatol Online J
JT  - Dermatology online journal
JID - 9610776
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Dermatologic Agents)
RN  - 0 (Immunologic Factors)
RN  - 0 (Immunosuppressive Agents)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - FU77B4U5Z0 (Ustekinumab)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Dermatologic Agents/*therapeutic use
MH  - Facial Dermatoses/*drug therapy/pathology
MH  - Female
MH  - Humans
MH  - Immunologic Factors/therapeutic use
MH  - Immunosuppressive Agents/therapeutic use
MH  - Injections, Intralesional
MH  - Lupus Erythematosus, Discoid/*drug therapy/pathology
MH  - Methotrexate/therapeutic use
MH  - Middle Aged
MH  - Rituximab/therapeutic use
MH  - Treatment Failure
MH  - Ustekinumab/*therapeutic use
EDAT- 2017/03/23 06:00
MHDA- 2017/10/12 06:00
CRDT- 2017/03/23 06:00
PHST- 2017/01/20 00:00 [received]
PHST- 2017/01/20 00:00 [accepted]
PHST- 2017/03/23 06:00 [entrez]
PHST- 2017/03/23 06:00 [pubmed]
PHST- 2017/10/12 06:00 [medline]
PST - epublish
SO  - Dermatol Online J. 2017 Jan 15;23(1).